A Phase II Trial of PledOx in combination with the cancer theraphy FOLFOX6 in patients with cancer in the large inestine

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001367-76

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary Objective Dose Escalation Phase: To characterize the prevalence, severity, drug-relatedness and seriousness of adverse events of PledOx in two doses Primary Objective Randomised Treatment Phase: Assess the efficacy of two different doses of PledOx when added to FOLFOX6 chemotherapy as measured by protection from FOLFOX6 toxicity on neutropenia grade 3 and 4 (NCI-CTCAE v4)


Critère d'inclusion

  • Metastatic colorectal cancer